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Abstract
Oxidative stress leads to the activation of the Nuclear factor-erythroid-2-related factor 2 (Nrf2) pathway. While most stud-
ies have focused on the activation of the Nrf2 pathway after single chemical treatment, little is known about the dynamic 
regulation of the Nrf2 pathway in the context of repeated exposure scenarios. Here we employed single cell live imaging to 
quantitatively monitor the dynamics of the Nrf2 pathway during repeated exposure, making advantage of two HepG2 fluo-
rescent protein reporter cell lines, expressing GFP tagged Nrf2 or sulfiredoxin 1 (Srxn1), a direct downstream target of Nrf2. 
High throughput live confocal imaging was used to measure the temporal dynamics of these two components of the Nrf2 
pathway after repeated exposure to an extensive concentration range of diethyl maleate (DEM) and tert-butylhydroquinone 
(tBHQ). Single treatment with DEM or tBHQ induced Nrf2 and Srxn1 over time in a concentration-dependent manner. The 
Nrf2 response to a second treatment was lower than the response to the first exposure with the same concentration, indicating 
that the response is adaptive. Moreover, a limited fraction of individual cells committed themselves into the Nrf2 response 
during the second treatment. Despite the suppression of the Nrf2 pathway, the second treatment resulted in a three-fold higher 
Srxn1-GFP response compared to the first treatment, with all cells participating in the response. While after the first treat-
ment Srxn1-GFP response was linearly related to Nrf2-GFP nuclear translocation, such a linear relationship was less clear 
for the second exposure. siRNA-mediated knockdown demonstrated that the second response is dependent on the activity of 
Nrf2. Several other, clinically relevant, compounds (i.e., sulphorophane, nitrofurantoin and CDDO-Me) also enhanced the 
induction of Srxn1-GFP upon two consecutive repeated exposure. Together the data indicate that adaptation towards pro-
oxidants lowers the Nrf2 activation capacity, but simultaneously primes cells for the enhancement of an antioxidant response 
which depends on factors other than just Nrf2. These data provide further insight in the overall dynamics of stress pathway 
activation after repeated exposure and underscore the complexity of responses that may govern repeated dose toxicity.
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Introduction
Chemical exposure leads to the activation of various cel-
lular stress response pathways (Jennings et al. 2013; Souza 
et al. 2017). These cellular stress response pathways are 
typically activated to initiate repair of cell injury and/or to 
adapt cells to possible subsequent harmful situations (Baird 
and Dinkova-Kostova 2011; Kensler et al. 2007). Alterna-
tively, cell injury may initiate the activation of cell death 
programs to switch on self-demise of cells (Danial and Kors-
meyer 2004; Fulda et al. 2010). Although these are realistic 
conceptual considerations, so far there is little data on how 
individual cells within an entire population respond upon 
repeated exposure. This is largely related to the experimental 
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limitations that prohibit a high dimensional analysis of the 
cellular stress responses at different concentrations and time 
points in populations of individual cells. To improve our 
basic understanding of cellular responses to repeated dosing 
scenarios, we here apply time-resolved live cell imaging of 
cellular stress response activation, focusing on the Nuclear 
factor-erythroid-2-related factor 2 (Nrf2) mediated antioxi-
dant stress response signaling pathway.
The Nrf2 pathway plays a role in protection against 
chemicals with soft electrophile properties and that prop-
agate the generation of reactive oxygen species (ROS), 
which may lead to oxidative stress with cell death as an 
ultimate outcome (Ryter et al. 2007). Such enhanced oxi-
dative stress is typically counteracted through activation of 
the adaptive antioxidant cellular stress response pathway 
(Deshmukh et al. 2017; Ma 2013) which involves the acti-
vation of the Nrf2 pathway as the most critical component 
(Itoh et al. 1997; Meakin et al. 2014; Vomund et al. 2017). 
Nrf2 itself is a ‘Cap ‘n’ Collar’ (CNC) basic-region leucine 
zipper transcription factor. Under basal unstressed cellular 
conditions, a single Nrf2 protein is bound to two Kelch-
like ECH-associated proteins (Keap1) (Keum and Choi 
2014; Zipper and Mulcahy 2002). Keap1-bound Nrf2 is 
poly-ubiquitinated, targeting it for degradation (Kobayashi 
et al. 2004; Zhang et al. 2004). In response to oxidative 
stress and soft-electrophilic chemical exposure Keap1 is 
modified (Baird and Dinkova-Kostova 2013). Modification 
of Keap1 happens on a subset of its 27 cysteine residues 
(Holland and Fishbein 2010). For example, the chemi-
cals diethyl maleate (DEM) and tert-butylhydroquinone 
(tBHQ) can bind to cysteine residue 151; This leads to 
ubiquitination of Keap1, therefore degradation of Nrf2 
cannot take place (Holland and Fishbein 2010; Kobayashi 
et al. 2009). Current models indicate that modified Keap1 
remains occupied by Nrf2, driving accumulation of newly 
translated Nrf2, its translocation into the nucleus and 
binding and activating the antioxidant response element 
(ARE) in various target genes (Bryan et al. 2013; Itoh 
et al. 1997). Nrf2 downstream genes encode for a diverse 
set of adaptive programs to protect against the oxidative 
stress environment, exemplified by the upregulation of 
glutamate-cysteine ligase modifier (GCLM), heme oxy-
genase 1 (HMOX1), NAD(P)H quinone oxidoreductase 1 
(NQO1), and sulfiredoxin1 (SRXN1). Here, we focus on 
the regulation of Srxn1, a bona fide Nrf2 target protein 
that is involved in the reduction of oxidized peroxiredoxin, 
a family of peroxidases which catalyzes the reduction of 
 H2O2 and alkyl hydroperoxides (Chang et al. 2004; Keum 
et al. 2006; Soriano et al. 2008). Nrf2 pathway activation 
is thought to lead to an overall protection against oxida-
tive stress, with the expectation that a similar repeated 
exposure would limit the antioxidant response, since suffi-
cient protection is already available. Indeed, Nrf2 pathway 
activation typically leads to protection against pro-oxidant 
response (Itoh et al. 1997; Kensler et al. 2007; Wu et al. 
2012). However, so far little is known on the dynamic 
modulation of Nrf2 under such repeated exposure condi-
tions and whether limitations in the anticipated adaptation 
exist. Moreover, it remains unclear whether such adapta-
tion is reflected by suppression of Nrf2 pathway activation 
in general or, alternatively, potential priming of the Nrf2 
pathway leading to stronger pathway activation upon a 
repeated exposure. Understanding the outcome of diverse 
exposure scenarios is important for rational decision mak-
ing on the safety assessment of repeated exposure.
A few reports exist on repeated exposure to known 
Nrf2 inducers. Mathew et al. found a stronger induction 
of Nrf2-dependent gene expression in primary human 
skin fibroblasts after repeated exposure to sulphoraphane 
compared to single exposure. Interestingly, an optimal 
concentration for repeated sulphoraphane exposure was 
determined that provided maximal protection against radi-
ation injury (Mathew et al. 2014). In addition, Bergström 
et al. showed an ongoing accumulation of Nqo1 protein, 
a downstream target of the Nrf2 pathway, in astrocytes 
treated with 10 µM sulphoraphane for 4 h per day over a 
time span of 4 days (Bergstrom et al. 2011). While these 
findings support different outcomes of single exposure 
compared to repeated exposure to Nrf2 activating agents, 
these studies have provided little insight into the actual 
behavior of Nrf2 or downstream Nrf2 target activity dur-
ing repeated exposure at a single-cell level.
We have previously reported the systematic characteri-
zation and application of a panel of fluorescent protein 
reporters to follow individual components of the Nrf2 
pathway: Keap1, Nrf2, and Srxn1 (Hiemstra et al. 2017; 
Wink et al. 2017, 2018). We used BAC transgenomics to 
tag these components with GFP and follow their behavior 
in individual cells over time using high-throughput con-
focal imaging (Wink et al. 2017). Here we applied these 
reporter cell lines to investigate the effect of two earlier 
mentioned, well-known inducers of the Nrf2 pathway, 
DEM and tBHQ, on the dynamics of Nrf2 and Srxn1 acti-
vation under different repeat exposure scenarios. DEM 
is an alkylating agent able to deplete cellular glutathione 
(GSH) levels by direct conjugation with GSH or via glu-
tathione S-transferase (Casey et al. 2002; Priya et al. 2014; 
Yamauchi et al. 2011). tBHQ is the metabolite of butylated 
hydroxyanisole, a synthetic phenolic antioxidant, that acts 
as a redox cycler to generate ROS (Imhoff and Hansen 
2010). In the present study, we used DEM and tBHQ to 
unravel the dynamics of Nrf2 pathway activation during 
repeated exposure. Our current data provide direct evi-
dence for distinct dynamics of Nrf2 activation during a 
first and second treatment regimen as well as for priming 
of the pathway initiated during the first treatment, thus 
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promoting an enhanced activation of the Nrf2 target gene 
SRXN1 during a second treatment regimen.
Methods
Chemicals
Tert-butylhydroquinone (tBHQ, CAS: 1948-33-0), diethyl 
maleate (DEM, CAS: 141-05-9), L-sulphoraphane (CAS: 
142825-10-3), and nitrofurantoin (CAS: 67-20-9) were 
obtained from Sigma–Aldrich. and Bardoxolone methyl 
(CDDO-Me, CAS: 218600-53-4) was obtained from Cay-
man Chemicals/Bio-Connect. All compounds were dis-
solved in 100% dimethyl sulfoxide (DMSO, CAS: 67-68-5) 
from Sigma–Aldrich, to obtain aliquots with stock concen-
trations of 0.1 M.
Cell culture
The human hepatoma HepG2 cell line was obtained from 
American Type Culture Collection (ATCC ® HB-8065™, 
Wesel, Germany). Previously, HepG2-GFP reporter 
cells were developed and characterized for Nrf2 and 
Srxn1 (Wink et al. 2017). Briefly, cell lines were con-
structed with GFP reporter genes located on bacterial 
artificial chromosomes (BACs) that encode C-terminal 
GFP-tagged fusion proteins, following a selection with 
500 µg/mL G-418. For more information, see (Poser et al. 
2008). Cells were grown in Dulbecco’s Modified Eagle 
Medium (DMEM) high glucose, supplemented with 10% 
(v/v) fetal bovine serum (FBS), 25 U/mL penicillin, and 
25 µg streptomycin. Cells were used for experiments until 
passage 20. Cells were seeded in 384-well plates (7000 
cells/well), 2 days before exposure. Cells were exposed 
to concentrations in the range of 12.5–200 µM of DEM 
or tBHQ, 2.5–50 µM sulphoraphane, 15.6–250 µM nitro-
furantoin, and 25–500 nM CDDO-Me. DMSO (0.1% v/v) 
and DMEM were used as negative controls.
Cell treatment and repeated exposure scenarios
Two different repeated exposure scenarios were used. In 
scenario 1, 8-h first exposure was followed by 8-h second 
exposure, i.e., in total 16 h of live cell imaging. In scenario 
2, 24-h first exposure was followed by 24-h second expo-
sure, i.e, in total 48 h of live cell imaging (Fig. 1a). For both 
scenarios we used 9 different concentrations of DEM and 
tBHQ (12.5, 25, 50, 75, 100, 125, 150, 175, 200 µM). All 
possible combinations of concentrations in the first and sec-
ond exposure were tested. Furthermore, scenario 2 was also 
used to test the effect of repeated exposures for five differ-
ent concentrations of sulphoraphane (2.5, 5, 10, 25, 50 µM), 
nitrofurantoin (15.6, 31.3, 62.5, 125, 250 µM), and CDDO-
Me (25, 50, 100, 250, 500 nM). In these experiments, we 
employed the same concentration of the compound during 
the second as during the first exposure.
siRNA transfection
siGENOME SMARTpool siRNAs were obtained from 
Dharmacon: siKEAP1, siNFE2L2, siSRXN1, siMAFF, and 
siMAFG. Upon arrival, siRNAs were resuspended follow-
ing the manufacturer’s description. siRNAs were diluted 
in 1x siRNA buffer (Dharmacon, USA) to a final concen-
tration of 1 µM. 5 µl siRNA solution/well (96-well plate) 
was used. Interferin (Westburg/PolyPlus, NL) was used as a 
transfection agent. Srxn1-GFP HepG2 cells were seeded and 
transfected in a 96-well plate (23,000 cells/well). 72 h after 
transfection, cells were exposed to the different chemicals as 
described above followed by high content imaging.
Confocal microscopy
Live cell confocal imaging was performed on a Nikon 
Eclipse Ti confocal microscope equipped with four lasers: 
408, 488, 561, and 633 nm. A 20× dry PlanApo VC NA 
0.75 was used. 384-well microclear imaging plates (micro-
clear, Greiner) were seeded with 7000 cells/well. Prior to 
exposure,  Hoechst33342 100 ng/mL was added to the wells to 
stain nuclei. Subsequently, Hoechst-containing medium was 
washed away and medium (25 µL) that contained 100 nM 
propidium iodide (PI) was added to allow measurement of 
cell death during imaging. 25 µL/well of compound contain-
ing medium was added to wells. Images were taken every 
hour for the indicated time periods.
TempO‑Seq transcriptome analysis
HepG2-WT cells were plated in 96-well plates (20,000 cells/
well) and exposed to 100 µM DEM or tBHQ, with three 
independent biological replicates. After 24-h exposure, the 
plates where washed with 200 µl PBS and lysed with 50 µl 
BioSpyder 1× lysis buffer for 15 min at room temperature. 
After this step, plates were frozen at − 80 °C. Next, the 
lysate plates were shipped on dry ice to BioSpyder technolo-
gies where the TempO-Seq assay was conducted (Yeakley 
et al. 2017). Returned gene transcription data were further 
analyzed using the Deseq2 package in R allowing to cal-
culate the log2fold change and the corresponding standard 
error (lfcSE), respectively, to the base line value (medium 
only, no treatment).
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Image processing and analysis
Cell segmentation and quantification was performed 
with CellProfiler version 2.1.1 (Hiemstra et  al. 2017; 
Kamentsky et al. 2011). To segment the nuclei from the 
background and each other, we used an ImageJ plugin for 
CellProfiler based on watershed masked clustering (WMC) 
as described before (Yan and Verbeek 2012). In brief, the 
method consists of three steps. First, the image is divided 
into intensity regions and starting from local maximum 
Fig. 1  Schematic representation of the in  vitro exposure scenarios 
and metrics. a Schematic overview of the two exposure scenarios. 
b Illustration of the metrics used for comparison of the dynamic 
behavior between the first and second exposure: Max highest value 
reached within experimental time frame. hMax half of the Max value, 
thMax time to reach hMax. The thMax is calculated by interpolating 
the two data points closest to half of the Max value (illustrated by 
orange line). c Confocal microscopy images of the Nrf2-GFP signal 
(at 8 h) and the Srxn1-GFP signal (at 24 h) after exposure to different 
concentrations of DEM with and without nuclear staining (Hoechst). 
Data are normalized per experiment and error bars depict the SEM, 
based on n = 3 (for Nrf2-GFP) and n = 4 (for Srxn1-GFP) experi-
ments. AU arbitrary units. (Color figure online)
Archives of Toxicology 
1 3
intensities, the watershed region is expanded. Second, a 
weighted fuzzy C-means clustering algorithm is applied 
to find an optimal threshold that separates background 
and nucleus for this region. Third, to correct nuclei that 
were erroneously subdivided into two different regions 
(i.e., that were actually a single nucleus), the algorithm 
merges nuclei from adjacent regions having the same ori-
entation. We used the output of the WMC module, i.e., 
the segmented nuclei areas, to quantify the intensity of 
nuclear Nrf2-GFP and PI. To determine the intensity of 
Srxn1-GFP in the cytoplasm, we applied the propagation 
setting in CellProfiler (“identify-secondary-objects mod-
ule”), employing the nuclei as seeds. This implies that 
CellProfiler takes the outer border of the nuclei as starting 
points to go outwards in a recursive manner until pixels are 
no longer positive for GFP or belong to a neighboring cell. 
In cases with high background levels that precluded cor-
rect cytoplasmic segmentation employing the propagation 
setting, we used the ‘distance B’ setting in CellProfiler 
(“identify-secondary-objects module”). In this setting, the 
nucleus is expanded by a fixed amount of pixels (using 30 
pixels for our case), and in this region the background and 
GFP signal is distinguished.
Nrf2-GFP-intensities of single cells are calculated by 
taking the mean of all the pixels in a segmented nucleus. 
For Srxn1, the integrated GFP-intensity in the cyto-
plasm has been calculated with the propagation or dis-
tance B setting. We employed min–max normalization to 
these values, i.e., we scaled the mean GFP-intensities of 
individual cells per experiment between 0 and 1, to be 
able to compare the biological replicates. A cell was con-
sidered GFP-positive, when its normalized GFP-intensity 
exceeded a threshold equal to the third quartile of the 
GFP-intensity distribution of cells treated with medium 
(negative control) during the first exposure. To determine 
this GFP-intensity distribution, all cells were individu-
ally included as were all time points of the first exposure. 
The PI-intensity within the segmented nuclei was used to 
decide whether a cell was considered dead or alive, based 
on an analysis of PI- and Srxn1-GFP-intensities. Cells 
with a PI-intensity of 0.2 or higher never reached a high 
level of Srxn1-intensity (not shown). Therefore, 0.2 was 
chosen as a cut-off value, and cells above this PI-intensity 
were considered dead. Note that the same PI-intensity 
threshold was applied for the Nrf2-GFP reporter cell line.
To allow comparison of the cellular response during the 
first exposure with that during the second exposure, we 
first subtracted the mean intensity of the last time point of 
the first exposure from the mean intensity of the second 
exposure. To visualize the strength of the response, we 
focused on the maximum value (Max), i.e., the highest 
mean intensity at any time point (Fig. 1b). To quantify 
the speed of the response, the time to reach half of the 
Max value (thMax) was calculated. We used linear inter-
polation to estimate the time it takes to reach the half-
maximal value (hMax). Significance is determined using 
a one-sided welch two sample t-test.
Results
Dynamics of Nrf2 and Srxn1 activation after single 
treatment with DEM and tBHQ
To assess the dynamics of Nrf2 pathway activation we 
used two model compounds, DEM and tBHQ, two small 
molecules that target cysteine residues in Keap1, leading 
to activation of the Nrf2 pathway (Holland and Fishbein 
2010; Kobayashi et al. 2009). Here, we first systematically 
compared the dynamics of Nrf2 activation by DEM and 
tBHQ upon a single dosing regimen by using confocal 
microscopy to monitor the stabilization and nuclear trans-
location of Nrf2-GFP and subsequent induction of Srxn1-
GFP, a direct target gene of Nrf2 (Fig. 1c). HepG2 Nrf2-
GFP and HepG2 Srxn1-GFP reporter-cells were exposed to 
different concentrations (12.5–200 µM) of DEM and tBHQ 
followed by live cell imaging for 24 h (Fig. 2a, b). Both 
compounds caused Nrf2-GFP stabilization and transloca-
tion into the nucleus in a concentration-dependent manner 
(Fig. 2a). Nrf2 reaches its hMax after approximately 2 h 
of exposure to DEM or tBHQ, independent of the con-
centration (Fig. 2c). Overall maximal values of nuclear 
Nrf2-GFP were similar for DEM and tBHQ, although at 
high concentrations of tBHQ a sustained nuclear pres-
ence of Nrf2-GFP was observed (Fig. 2a). As anticipated, 
Srxn1-GFP was activated later than Nrf2-translocation 
to the nucleus (Fig. 2a–c). We observed slightly higher 
maximum values of Srxn1-GFP-intensity after treatment 
with tBHQ, likely due to the sustained Nrf2 activation at 
high tBHQ concentration. The Srxn1-response reaches its 
thMax consistently after approximately 8 h of exposure, 
6 h later than the thMax of Nrf2 nuclear entry (Fig. 2c). 
We observed a linear relationship between the maximal 
Nrf2- Srxn1-GFP-intensities (Fig. 2d). Moreover, this 
relation was compound-specific, with different slopes for 
DEM (slope = 0.48) and tBHQ (slope = 0.71).
Dynamics of Nrf2 and Srxn1 activation 
after repeated dosing
There is little understanding on how prior activation of 
Nrf2 allows adaptation of the cell physiology and adjust-
ment to a secondary Nrf2 activation response. We con-
sidered two different scenarios: (1) a secondary exposure 
at a time point when the Nrf2 response was not yet back 
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Fig. 2  Time–response curves of Nrf2 and Srxn1 activation during 
24 h exposure to DEM or tBHQ in a dose range of 12.5–200 µM. a 
Average Nrf2-GFP signal in the nucleus over time. b Average Srxn1-
GFP signal in the cytoplasm over time. c thMax for Nrf2 and Srxn1, 
for both DEM and tBHQ. d Comparison of the maximal Nrf2-GFP 
and Srxn1-GFP-intensity reached after 24 h treatment with different 
concentrations of DEM or tBHQ (concentration indicated by symbol 
size)
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to baseline levels and adaptation not yet fully maximal; 
(2) a secondary exposure at a time point when the Nrf2 
response as well as the adaptation program is largely com-
pleted (see Figs. 1a, 2a, b). We first systematically evalu-
ated the first scenario and treated cells for 8 h with differ-
ent concentrations of DEM or tBHQ followed by a second 
exposure matrix at identical concentrations (Fig. 3). As 
for our initial experiment with single dosing (see Fig. 2), 
the Nrf2-GFP response showed a peak after approxi-
mately 2 h and subsequently slightly declined (Fig. 3a, 
b). Interestingly, a second treatment after 8 h caused a 
further (re)activation of the Nrf2-GFP response, in par-
ticular when the first concentration was lower than the 
second concentration. However, this was not so strongly 
Fig. 3  Time–response curves of Nrf2 and Srxn1 activation for short 
repeat exposure scenario (8 h + 8 h). Cells were exposed to DEM or 
tBHQ at the start and re-exposed after 8 h with indicated concentra-
tions. a, b Average Nrf2-GFP-intensity in the nucleus over time after 
exposure to DEM (a) and tBHQ (b). c, d Average Srxn1-GFP-inten-
sity in the cytoplasm over time after exposure to DEM (c) and tBHQ 
(d). Data are normalized per experiment and error bars depict the 
SEM; based on n = 3 experiments
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observed when the cells were first treated with the highest 
concentration of 200 µM, suggesting that the physiological 
response to activate the Nrf2 pathway was already satu-
rated under this condition (Fig. 3a, b). The enhanced acti-
vation of Nrf2-GFP after a second exposure did not have 
major consequences for the activation of the downstream 
target Srxn1 (Fig. 3c, d). Thus, although after 8 h from 
the first treatment the Srxn1-GFP induction was already 
initiated, a second treatment only marginally affected 
the Srxn1-GFP induction, in spite of the doubling of the 
Nrf2-GFP response for some concentration pairs (e.g., the 
50–200 µM combination for DEM). These data suggest 
that the 8-h repeated exposure scenario does not initiate 
clear adaptation, neither for DEM nor for tBHQ treatment.
Next, we determined the effect of repeated exposure at 
24 h intervals (scenario 2). We monitored the Nrf2-GFP 
and Srxn1-GFP response for 48 h, with second treatment 
initiation at 24 h. The same concentration matrix for the first 
Fig. 4  Time–response curves of Nrf2 and Srxn1 activation for long 
repeat exposure scenario (24 h + 24 h). Cells were exposed to DEM 
or tBHQ at the start and re-exposed after 24 h. a, b Average Nrf2-
GFP signal in the nucleus over time after exposure to DEM (a) and 
tBHQ (b). c, d Average Srxn1-GFP signal in the cytoplasm over time 
after exposure to DEM (c) and tBHQ (d). Data are normalized per 
experiment and error bars depict the SEM; based on n = 3 (for Nrf2-
GFP) and n = 4 (for Srxn1-GFP) experiments
Archives of Toxicology 
1 3
and second treatment was used as for scenario 1. For both 
DEM and tBHQ we observed a suppression of the Nrf2-
GFP response when identical concentrations for first and 
second treatment were considered (see, e.g. 50 µM/50 µM 
and 100 µM/100 µM repeat dosing scenarios in Fig. 4a, b). 
When the concentration of the second treatment was higher 
than for the first treatment, a Nrf2-GFP response equal to or 
higher than the first response was observed. This was in par-
ticular the case for tBHQ, where the highest concentration 
of tBHQ caused a sustained activation of Nrf2-GFP during 
the second exposure (Fig. 4b). This response of Nrf2-GFP 
was not reflected in the behavior of its target Srxn1-GFP. In 
general, despite the suppression of the Nrf2-GFP response, 
the Srxn1-GFP of the second treatment was stronger com-
pared to the first treatment, both with respect to response 
rate as well as the amplitude of the Srxn1-GFP response 
(Fig. 4c, d). Only the highest concentration of tBHQ did not 
demonstrate such a strong secondary Srxn1-GFP response 
(Fig. 4d). This was likely related to the fact that a secondary 
treatment with 200 µM tBHQ caused cell death in ~ 25% of 
the cells (Supplementary Fig. 1), indicating that this con-
centration was close to the tipping point towards onset of 
cell death. This coincided with the sustained accumulation 
of Nrf2-GFP in the nucleus. In conclusion, these data sug-
gest that activation of the Nrf2 pathway response results in 
an adaptation of Nrf2 activation, in particular at late time 
points. In addition, such adaptation of Nrf2 activation does 
not imply suppression of downstream target genes of Nrf2. 
Intriguingly, the observed adaptation is in fact associated 
with an enhanced induction of Srxn1-GFP, irrespective of 
suppression of Nrf2-GFP activation.
Population dynamics of Nrf2 and Srxn1 activation 
during repeated exposure
So far, our results have demonstrated the effect of repeated 
treatment at the entire population level. The strength of our 
live cell imaging approach is that we can determine the 
commitment of individual cells within the entire population 
during both the first and second treatment with DEM and 
tBHQ. Therefore, next we asked whether a difference in the 
response during the repeated exposure was related to differ-
ences in the overall commitment of individual cells into the 
stress response activation. For this purpose, we determined 
a background GFP-threshold value based on measurements 
under control situations. We considered cells to be com-
mitted to the response when the GFP-values exceed this 
background threshold. We observed that there was a drastic 
commitment of more than 90% of the cells with respect to 
Nrf2-GFP activation within the first 2 h after the first treat-
ment with the various concentrations of DEM and tBHQ. 
The fraction of committing cells then slowly declined to 
baseline levels over time if there was no second exposure. 
For the second treatment we observed an equally fast 
increase in individual cell commitment, and prior treatment 
hardly affected the commitment of cells (Fig. 5), despite that 
the population-level amplitude of activation was lower com-
pared to the first treatment (see Fig. 4). The commitment to 
Nrf2-GFP activation was typically shorter in duration for the 
second than for the first exposure (Fig. 5a, b). Interestingly, 
for high concentrations of tBHQ the overall commitment of 
Nrf2-GFP activation remained high.
With respect to the Nrf2-mediated activation of the 
Srxn1-GFP response, almost all cells committed already 
during the first treatment period, with a lag phase of up to 
4 h (Fig. 5c, d). The second treatment did not further affect 
the commitment of individual cells into the response, besides 
that the overall amplitude of the Srxn1-GFP response was 
higher (compare Figs. 4, 5). Together, these data indicate 
that at the individual cell level a clear adaptation of Nrf2-
GFP activation occurs, where the overall commitment to 
Nrf2-GFP activation is sustained for a shorter period in the 
second treatment compared to the first treatment period.
Differential activation dynamics for Nrf2 and Srxn1 
activation for first and second treatment regimens
The analysis above indicated differences in the commit-
ment of cells with respect to Nrf2 activation. Since in our 
experimental setup we recorded the reporter activities for 
all treatment conditions with ~ 1-h time resolution, we next 
extracted the maximal Nrf2-GFP and Srxn1-GFP activation 
and the speed of activation onset during the first and sec-
ond exposure. The maximum intensity of Nrf2-GFP for the 
first 24 h exposure was slightly higher than for the second 
24 h, supporting adaptation of the Nrf2 response (Fig. 6a). 
In contrast, the maximum response for Srxn1-GFP was up 
to three times higher after the second treatment (Fig. 6b). 
We also considered potential differences in the dynamics 
of both Nrf2-GFP and Srxn1-GFP activation. The thMax 
was hardly affected by concentration or compound, except 
for the highest repeat concentrations of tBHQ at which the 
Nrf2 pathway does not recover and the concentration of 
Nrf2 in the nucleus increases for the entire 48 h treatment 
duration (Fig. 6c, d). Interestingly, despite similar Nrf2-GFP 
dynamics between the first and second exposure, the thMax 
for Srxn1-GFP activation declined by almost a factor two, 
from ~ 8 to ~ 4 h. This is consistent with the notion that 
the enhanced Srxn1 upregulation is part of an adaptation 
program to control prolonged exposure to soft electrophiles 
such as DEM and tBHQ. Because of the opposite direc-
tion of the response, i.e. the reduced response of Nrf2-GFP 
and the increased response of Srxn1-GFP during the sec-
ond treatment condition, the linear relationship between 
Nrf2-GFP and Srxn1-GFP activation that we observed for 
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the first exposure was less clearly present for the second 
treatment period (Fig. 6e). Moreover, the slope difference 
between DEM and tBHQ was no longer apparent. These 
data together indicate that during repeated treatment with 
soft electrophilic chemicals, different mechanisms take part 
in the cellular stress response activation of the Nrf2 pathway 
for the first and for subsequent exposures.
Secondary enhanced activation of Srxn1 expression 
is dependent on the Keap1/Nrf2 pathway
We next investigated the underlying mechanism of the Srxn1 
induction during repeated exposure. Because SRXN1 is a 
well-described Nrf2 target gene (Soriano et al. 2008), we 
investigated whether both the first and second induction of 
Srxn1-GFP expression depended on the Keap1/Nrf2 path-
way using siRNA knockdown experiments. siSRXN1 inhib-
ited the induction of SRXN1 during both the first and the 
second exposure to DEM and tBHQ (Fig. 7a, b), indicating 
that our knockdown condition was effective. Since Keap1 
targets Nrf2 for degradation, we anticipated that knockdown 
of KEAP1 would enhance Nrf2 activity and promote Srxn1-
GFP expression. Indeed, siKEAP1 enhanced both the first 
and second induction of Srxn1-GFP by DEM and tBHQ 
(Fig. 7a, b). Finally, knockdown of Nrf2 itself through siN-
FE2L2 led to inhibition of Srxn1 induction during first and 
second exposure (Fig. 7a, b), demonstrating that the strong 
induction of Srxn1 during the second response depends pri-
marily on Nrf2.
Fig. 5  Commitment of individual cells into the Nrf2 and Srxn1 
response during long repeat exposure scenario. Cells were exposed to 
DEM or tBHQ at the start and re-exposed after 24 h. a, b Fraction of 
cells whose nuclear Nrf2-GFP levels exceed background levels over 
time, after exposure to DEM (a) and tBHQ (b). c, d Fraction of cells 
whose cytoplasmic Srxn1-GFP levels exceed background levels, after 
exposure to DEM (c) and tBHQ (d). Data are normalized per experi-
ment and error bars depict the SEM; based on n = 3 (for Nrf2) and 
n = 4 (for Srxn1) experiments
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MAF-transcription factors are co-activators of Nrf2 
as well as downstream targets of Nrf2, offering a poten-
tial explanation for the increased Srxn1 induction during 
repeated exposure. However, we did not observe an induc-
tion of either MAFF or MAFG gene expression at 24 h after 
the first treatment with DEM or tBHQ (Fig. 7c). Moreo-
ver, knockdown of neither MAFF nor MAFG inhibited the 
induction of Srxn1-GFP during either the first or second 
exposure (Fig. 7d), suggesting that MAFs do not provide an 
explanation for the enhanced Srxn1 induction in the second 
exposure. Altogether, these data indicate a primary role for 
Nrf2 in the regulation of secondary Srxn1 induction.
Enhancement of secondary Srxn1 induction 
by other compounds including drugs that activate 
the Nrf2 pathway
Finally, we evaluated whether the enhanced secondary 
response was also observed for compounds where Nrf2 
activation is related to the direct pharmacology or off-tar-
get effects. Specifically, we included bardoxolone methyl 
(CDDO-Me) (Cleasby et al. 2014; Wang et al. 2017), sul-
phoraphane (Alumkal et al. 2015; Lynch et al. 2017), and 
nitrofurantoin (Herpers et al. 2016; Tsuchiya et al. 2018), 
each of which activates the Nrf2 pathway at a different 
concentration range. Evaluation of Srxn1-GFP expression 
through imaging at 24 and 48 h post exposure with CDDO-
Me (250 nM), sulphoraphane (10 µM) and nitrofurantoin 
(250 µM) demonstrated that Srxn1 was induced at 24 h 
and that this induction was further enhanced by a second 
Fig. 6  Quantitative analysis of Nrf2 and Srxn1 activation dynamics 
during first and second treatment periods. a, b The maximal values 
reached within 24  h after the first or second exposure to DEM or 
tBHQ for Nrf2-GFP (a) and Srxn1-GFP (b). c, d thMax after the first 
or second exposure to DEM or tBHQ for Nrf2-GFP (c) and Srxn1 
(d). e Comparison of the maximal Nrf2-GFP and Srxn1-GFP values 
reached within 24 h after second exposure to DEM or tBHQ
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exposure from 24 to 48 h, similar as for exposure to DEM 
(Fig. 8a, b). In contrast, a continuous single treatment with 
these drugs for 48 h did not lead to a similar high Srxn1-
GFP level, except for CDDO-Me, which is likely due to 
the prolonged response this compound causes (Wink et al. 
2017). These data indicate that the enhancement of Srxn1 
expression during a secondary Nrf2 response is in general 
relevant for drugs that can activate the Nrf2 pathway.
Discussion
Our general understanding of the dynamics of cellular stress 
response pathway activation in repeated treatment scenarios 
is limited. Here, we systematically mapped the Nrf2 pathway 
adaptive response landscape of repeated exposure to two 
different soft electrophiles, DEM and tBHQ. We took advan-
tage of two biologically relevant fluorescent HepG2 reporter 
cell lines that allowed us to monitor the activation of Nrf2 
and its downstream target Srxn1 in individual cells over time 
using live cell confocal imaging. Our data indicate that cells 
adapted to oxidative stress: During a second treatment they 
have limited Nrf2 activation and a relatively short-lasting 
commitment, yet cells are primed to exhibit enhanced activa-
tion of Nrf2 downstream target Srxn1.
Our high-throughput analysis of Nrf2-GFP and Srxn1-
GFP activation for diverse concentrations demonstrated 
that there is a linear and compound-dependent relation-
ship between the maximal amount of Nrf2 in the nucleus 
after single exposure and the subsequent maximal amount 
of Srxn1 in the cytoplasm. Single exposure to DEM and 
tBHQ resulted in a concentration-dependent activation of 
both Nrf2 and Srxn1, with slightly different dynamics for 
both compounds. The different dynamics observed and the 
different correlation between Nrf2 and Srxn1 might be due 
to the different manners in which both compounds activate 
the Nrf2 pathway, involving both Keap1-dependent and 
-independent activation mechanisms (Bryan et al. 2013; Lee 
et al. 2001). Moreover, the half-life of DEM and tBHQ in the 
culture conditions may differ, offering a potential explana-
tion for differential activation dynamics of Nrf2, although 
this does not explain why there is a different Nrf2 to Srxn1 
ratio. The latter was in particular apparent for very high 
tBHQ concentrations.
For the first exposure, Nrf2-GFP reached hMax activation 
levels within 2 h, which was associated with an overall com-
mitment to Nrf2 activation of > 90% of the cells. Interest-
ingly, when a second exposure was initiated after 8 h both 
DEM and tBHQ could further promote Nrf2-GFP accumula-
tion, despite the fact that the response had not yet returned 
to baseline. Apparently, the machinery to produce newly 
synthesized Nrf2-GFP was not yet at its maximum capac-
ity, and/or there was still remaining Keap1 to be targeted 
by the electrophiles, further suppressing Nrf2 ubiquitina-
tion. Regardless, the increased amount of Nrf2-GFP did not 
equally enhance Srxn1 activation, as the amount of Srxn1-
GFP hardly changed. Thus, adaptation to electrophiles takes 
longer than 8 h, which is relevant for the design of repeated 
dose scenarios in the context of pharmacological modulation 
of the Nrf2 pathway, yet also for toxicant exposure scenarios 
in daily life that may cause Nrf2 pathway activation.
Two main observations indicate that adaptation at the 
level of Nrf2-GFP activation occurs during long-term (24 h) 
repeated treatment scenarios. First, the Nrf2-GFP nuclear 
accumulation was lower for the second treatment than 
for the first treatment. This effect was strongest when the 
same concentration was applied during the first and second 
treatment, but was also visible when the concentration of 
the second treatment was higher. Second, the overall time 
period that individual cells remained committed to Nrf2-
GFP nuclear accumulation was shorter for the second treat-
ment. This effect was observed both for DEM and tBHQ, 
although for tBHQ the overall commitment of the population 
after the second treatment did not reach the levels of the 
first exposure. The stabilization and nuclear accumulation 
of Nrf2 is known to reflect the activation of the oxidative 
stress sensing machinery (Kobayashi et al. 2006). Thus, if 
pro-oxidants affect the Cys residues of Keap1 more strongly, 
the degradation of Nrf2 is also more difficult. Because we 
observed less Nrf2-GFP in the nucleus and a shorter com-
mitment period for cells in the second compared to the first 
exposure, this suggests a limited targeting of the sensing 
machinery. Hence, during the second exposure both DEM 
and tBHQ may be more rapidly detoxified by the action of 
downstream Nrf2 targets, including Srxn1.
The adaptation to both DEM and tBHQ resulted in an 
unanticipated further upregulation of Srxn1-GFP. Thus, 
despite the relatively low response of Nrf2 after the second 
treatment, Srxn1-GFP showed a threefold increased induc-
tion. Given the critical role of Srxn1 in the antioxidant 
Fig. 7  siRNA mediated knockdown of different Nrf2 pathway 
proteins. a Time–response curves of Srxn1-GFP induction after 
treatment with DEM (100 µM) or tBHQ (100 µM) in mock condi-
tion or with siKEAP1, siNFE2L2 or siSRXN1. b Maximal Srxn1-
GFP-intensity at 24 h after exposure to DMSO (0.1%), DEM (100 
µM) or tBHQ (100 µM) and in mock condition or transfection with 
mock condition, siKEAP1, siNFE2L2 or siSRXN1. Significance 
is shown with a * based on a < 0.05 p value comparing the same 
treatment in the mock condition, hypothesizing that the siKEAP1 
knockdown gives a higher Srxn1-GFP-intensity, while the other si-
knockdowns have a lower Srxn1-GFP-intensity compared to mock. 
c Gene expression changes of MAFF, MAFG, and SRXN1 vs base-
line (i.e., medium sample just before treatment) 24 h after exposure to 
DMSO (0.1%), DEM (100 µM) or tBHQ (100 µM). d Time–response 
curves of Srxn1-GFP induction after treatment with DEM (100 µM) 
or tBHQ (100 µM) in mock condition or with siMAFF or siMAFG. 
Results are in all cases based on n = 3 experiments, with error bars 
depicting the SEM (a, b, d) or the lfcSE (c)
◂
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Fig. 8  Srxn1 induction following repeated exposure to various drugs. 
Srxn1-GFP reporter cells were exposed for either 24  h, or exposed 
for two time periods of 24 h, or for a single time period of 48 h to 
CDDO-Me (0.25 µM), DEM (50 µM), Nitrofurantoin (250 µM), Sul-
phoraphane (10 µM) or DMSO (0.1%). a Srxn1-GFP expression after 
chemical exposure. Significance is shown with a * based on a < 0.05 
p value comparing 24  h exposure or 48  h exposure to the repeated 
24 h exposure, hypothesizing that the repeated exposure has always 
the highest Srxn1-GFP-intensity. b Population commitment to Srxn1 
induction presented as density plot, platted as fraction of cells (y axis) 
expressing the Srxn1-GFP levels (x asis). Shown are average data of 
n = 3 experiments
Archives of Toxicology 
1 3
response (Baek et al. 2012; Soriano et al. 2008; Zhou et al. 
2015), we presume that this phenomenon is a critical com-
ponent of an adaptation program that primes cells to subse-
quent exposures and improves protection against oxidative 
stress. The Keap1/Nrf2 interaction was the main compo-
nent responsible for the enhanced secondary response, since 
knockdown of NFE2L2 strongly inhibited this response and 
knockdown of KEAP1 promoted it. Still, this enhanced 
response of Srxn1-GFP is likely not driven by Nrf2 alone, 
since the Nrf2-GFP nuclear activity was lower during the 
second exposure than during the first exposure. In our hands, 
knock-down of MAF-family transcriptional regulators 
MAFF and MAFG that can modulate Nrf2 transcriptional 
activity did not affect the enhanced Srxn1 induction. We, 
therefore, anticipate that other factors are involved in the 
secondary response that also themselves might be modulated 
as part of the primary response.
In the literature, some evidence has been presented for the 
accumulation of downstream targets of Nrf2 during repeated 
exposure. For example, Bergström et al. (2011) showed a 
daily accumulation of NQO1 mRNA and protein in astro-
cytes treated with 10 µM sulphoraphane for 4 h per day over 
a time span of 4 days. Interestingly, they did not find the 
same for HMOX1, which only exhibited an increase after 
the first exposure, but no further accumulation after repeated 
exposure. Similar conclusions with respect to NQO1 and 
HMOX1 were obtained by Mathew et  al. (2014), who 
treated human fibroblasts with different concentrations of 
sulphoraphane for 4 h per day over a time span of 3 days. To 
what extent these effects are related to activity of Nrf2 and/
or other factors remains unclear. Factors that govern Nrf2 
activity itself may also be relevant for the observed priming 
effects at the level of Srxn1-GFP induction. This could be 
related to post-translational modification of Nrf2 through for 
example phosphorylation or acetylation (Huang et al. 2000; 
Sun et al. 2009) or through the induction of transcriptional 
co-regulators that act in concert with Nrf2 to target specific 
genes, including for example p21 (Chen et al. 2009; Kat-
suoka et al. 2005). Alternatively, given the role of Keap1 in 
modulating Nrf2 changes in the overall Keap1/Nrf2 inter-
actome, modifications in this interactome may also effect 
Nrf2 activity. Keap1 is found as a homodimer associated 
with Cullin-3, which binds to the BTB (Bric a brac) domain 
of Keap1, and is anchored to the actin cytoskeleton (Waka-
bayashi et al. 2004). In addition, some proteins are able to 
bind to the free site at Keap1, like the p62 protein (Jiang 
et al. 2015), thereby competing with Nrf2 for this binding 
site. Because of such binding, the closed conformational 
state cannot be formed. Altered expression of proteins that 
interact with the Keap1/Nrf2 complex during the first treat-
ment may have consequences for the complex activity during 
a second treatment phase. Further work is required to iden-
tify the priming factors that drive an enhanced secondary 
anti-oxidant response and whether this response would occur 
for other bona fide Nrf2 target genes as well.
We set out to improve our fundamental understanding of 
cellular responses to repeat dosing scenarios. Altogether, our 
results demonstrate that cells previously exposed to pro-oxi-
dants exhibit an altered response pattern compared to ‘naive’ 
cells. Importantly, such responses are also observed for drug 
molecules that are currently used in the clinic and show a 
severe-DILI liability (nitrofurantoin) or are in clinical trials 
(CDDO-Me). This involves both suppression of the activity 
of the transcription factor Nrf2 and priming for an enhanced 
upregulation of anti-oxidant molecules. Our findings could 
imply that a ‘memory’ mechanism is in place within the 
Nrf2 pathway in which cells previously exposed to xenobi-
otics are better protected against similar future exposures. 
These results have implications for the comprehension and 
translation of stress response activation for chemical safety 
assessment in daily life and drug treatment situations which 
typically involve repeat dose exposure scenarios.
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